{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:57:07Z","timestamp":1789675027889,"version":"4.0.1"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bcp.2022.115046","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T23:02:48Z","timestamp":1650927768000},"page":"115046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The paradox of Myeloid Leukemia associated with Down syndrome"],"prefix":"10.1016","volume":"201","author":[{"given":"Avanti","family":"Gupte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman T.","family":"Al-Antary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaddanapudi","family":"Ravindranath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bcp.2022.115046_b0005","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1182\/blood.V80.9.2210.2210","article-title":"Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498","volume":"80","author":"Ravindranath","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2022.115046_b0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-1-4615-4811-9_43","article-title":"Down syndrome and acute myeloid leukemia. Lessons learned from experience with high-dose Ara-C containing regimens","volume":"457","author":"Ravindranath","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115046_b0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/1096-8628(20010801)102:2<205::AID-AJMG1454>3.0.CO;2-C","article-title":"Down syndrome before Down: a retrospect","volume":"102","author":"Berg","year":"2001","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.bcp.2022.115046_b0020","unstructured":"G. Fitzgerald, R.A. Schnebly, John Langdon Down (1828\u20131896), Embryo Project Encyclopedia, 2021."},{"key":"10.1016\/j.bcp.2022.115046_b0025","first-page":"1721","article-title":"Etude des chromosomes somatiques de neuf enfants mongoliens","volume":"248","author":"Lejeune","year":"1959","journal-title":"CR Acad. Sci. (Paris)"},{"issue":"7075","key":"10.1016\/j.bcp.2022.115046_b0030","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0140-6736(59)91892-6","article-title":"The somatic chromosomes in mongolism","volume":"1","author":"Jacobs","year":"1959","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bcp.2022.115046_b0035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1651-2227.1959.tb16408.x","article-title":"Cytogenetical observations in mongolism","volume":"48","author":"Book","year":"1959","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bcp.2022.115046_b0040","first-page":"872","article-title":"Acute lymphatic leukemia: Report of a case in eleventh month mongolina idiot","volume":"82","author":"Brewster","year":"1930","journal-title":"New Orleans Med. Surg. J."},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0045","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bjh.13096","article-title":"Haematopoietic development and leukaemia in Down syndrome","volume":"167","author":"Roberts","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"9199","key":"10.1016\/j.bcp.2022.115046_b0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down's syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bcp.2022.115046_b0060","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2022.115046_b0065","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2005-06-2448","article-title":"A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481","volume":"107","author":"Massey","year":"2006","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bcp.2022.115046_b0070","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1182\/blood-2011-04-350017","article-title":"Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971","volume":"118","author":"Gamis","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2022.115046_b0075","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.2008.07231.x","article-title":"Risk factors for early death in neonates with Down syndrome and transient leukaemia","volume":"142","author":"Muramatsu","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V99.1.245","article-title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome","volume":"99","author":"Zwaan","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00043426-200201000-00004","article-title":"Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study","volume":"24","author":"Al-Kasim","year":"2002","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115046_b0090","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-10-118810","article-title":"Treatment and prognostic impact of transient leukemia in neonates with Down syndrome","volume":"111","author":"Klusmann","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0095","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41375-021-01171-y","article-title":"Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome","volume":"35","author":"Yamato","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0100","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11899-016-0338-x","article-title":"Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update","volume":"11","author":"Bhatnagar","year":"2016","journal-title":"Current Hematologic Malignancy Reports"},{"issue":"2","key":"10.1016\/j.bcp.2022.115046_b0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/08880018709141272","article-title":"Megakaryoblastic leukemia and Down's syndrome: a review","volume":"4","author":"Zipursky","year":"1987","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.bcp.2022.115046_b0115","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2013-07-515148","article-title":"GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia","volume":"122","author":"Roberts","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00043426-200201000-00003","article-title":"Down syndrome and the transient myeloproliferative disorder: why is it transient?","volume":"24","author":"Taub","year":"2002","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115046_b0125","first-page":"76","article-title":"Down syndrome and leukemia: insights into leukemogenesis and translational targets","volume":"4","author":"Mateos","year":"2015","journal-title":"Transl. Pediatr."},{"issue":"43","key":"10.1016\/j.bcp.2022.115046_b0130","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1073\/pnas.1211405109","article-title":"Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21","volume":"109","author":"Roy","year":"2012","journal-title":"PNAS"},{"issue":"6224","key":"10.1016\/j.bcp.2022.115046_b0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/339446a0","article-title":"Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells","volume":"339","author":"Tsai","year":"1989","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0140","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/0092-8674(89)90940-9","article-title":"The erythroid-specific transcription factor Eryf1: a new finger protein","volume":"58","author":"Evans","year":"1989","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0145","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat. Genet."},{"issue":"19","key":"10.1016\/j.bcp.2022.115046_b0150","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1128\/MCB.25.19.8592-8606.2005","article-title":"GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1","volume":"25","author":"Kuhl","year":"2005","journal-title":"Molecular and cellular biology"},{"issue":"4","key":"10.1016\/j.bcp.2022.115046_b0155","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1182\/blood-2005-02-0551","article-title":"Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development","volume":"106","author":"Muntean","year":"2005","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bcp.2022.115046_b0160","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1128\/MCB.25.19.8592-8606.2005","article-title":"GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1","volume":"25","author":"Kuhl","year":"2005","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ccr.2006.06.002","article-title":"Activating alleles of JAK3 in acute megakaryoblastic leukemia","volume":"10","author":"Walters","year":"2006","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bcp.2022.115046_b0170","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/leu.2011.86","article-title":"Frequency and prognostic implications of JAK 1\u20133 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia","volume":"25","author":"Blink","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0175","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2141.2011.08948.x","article-title":"Molecular lesions in childhood and adult acute megakaryoblastic leukaemia","volume":"156","author":"Hama","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-4608(99)00072-2","article-title":"The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome","volume":"116","author":"Malkin","year":"2000","journal-title":"Cancer Genet. Cytogenet."},{"issue":"11","key":"10.1016\/j.bcp.2022.115046_b0185","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.bcp.2022.115046_b0190","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-03-491936","article-title":"Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome","volume":"122","author":"Nikolaev","year":"2013","journal-title":"Blood"},{"issue":"6551","key":"10.1016\/j.bcp.2022.115046_b0195","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf6202","article-title":"Mapping the cellular origin and early evolution of leukemia in Down syndrome","volume":"373","author":"Wagenblast","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bcp.2022.115046_b0200","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2014-06-581892","article-title":"MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome","volume":"125","author":"Shaham","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcp.2022.115046_b0205","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1101\/gad.4.11.1886","article-title":"Transcriptional activation and DNA binding by the erythroid factor GF-1\/NF-E1\/Eryf 1","volume":"4","author":"Martin","year":"1990","journal-title":"Genes Dev."},{"issue":"50","key":"10.1016\/j.bcp.2022.115046_b0210","doi-asserted-by":"crossref","first-page":"38949","DOI":"10.1074\/jbc.R000029200","article-title":"The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression","volume":"275","author":"Molkentin","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2022.115046_b0215","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1101\/gad.2.9.1089","article-title":"The human beta-globin gene 3' enhancer contains multiple binding sites for an erythroid-specific protein","volume":"2","author":"Wall","year":"1988","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/iub.2197","article-title":"GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome","volume":"72","author":"Garnett","year":"2020","journal-title":"IUBMB Life"},{"issue":"16","key":"10.1016\/j.bcp.2022.115046_b0225","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2010-02-267930","article-title":"Role of GATA-1s in early hematopoiesis and differences between alternative splicing in human and murine GATA-1","volume":"115","author":"Halsey","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bcp.2022.115046_b0230","doi-asserted-by":"crossref","first-page":"11598","DOI":"10.1073\/pnas.92.25.11598","article-title":"Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor","volume":"92","author":"Calligaris","year":"1995","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.bcp.2022.115046_b0235","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/10428190500485810","article-title":"Transcription factor GATA-1 and Down syndrome leukemogenesis","volume":"47","author":"Muntean","year":"2006","journal-title":"Leukemia Lymphoma"},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0240","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2002-11-3599","article-title":"Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21","volume":"102","author":"Rainis","year":"2003","journal-title":"Blood"},{"issue":"9369","key":"10.1016\/j.bcp.2022.115046_b0245","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(03)13266-7","article-title":"Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder","volume":"361","author":"Groet","year":"2003","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.bcp.2022.115046_b0250","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","article-title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","volume":"101","author":"Hitzler","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0255","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2003-09-3219","article-title":"Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome","volume":"103","author":"Shimada","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2022.115046_b0260","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2007-01-069542","article-title":"Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome","volume":"110","author":"Pine","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0265","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood-2004-04-1563","article-title":"Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome","volume":"104","author":"Taub","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0270","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0047-6374(97)00121-8","article-title":"Trisomy 21 and accelerated aging: DNA-repair parameters in peripheral lymphocytes of Down's syndrome patients","volume":"100","author":"Raji","year":"1998","journal-title":"Mech. Ageing Dev."},{"issue":"13","key":"10.1016\/j.bcp.2022.115046_b0275","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood-2008-11-190330","article-title":"Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome","volume":"114","author":"Cabelof","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2022.115046_b0280","first-page":"1393","article-title":"Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin","volume":"94","author":"Taub","year":"1999","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bcp.2022.115046_b0285","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1056\/NEJM199605303342203","article-title":"Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group","volume":"334","author":"Ravindranath","year":"1996","journal-title":"New England J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0290","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2007.13.2209","article-title":"Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421","volume":"26","author":"O'Brien","year":"2008","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2022.115046_b0295","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/sj.leu.2403927","article-title":"Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000","volume":"19","author":"Ravindranath","year":"2005","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0300","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00277-005-0045-5","article-title":"Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature","volume":"85","author":"Abildgaard","year":"2006","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0305","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.2005.05906.x","article-title":"Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials","volume":"132","author":"Rao","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.bcp.2022.115046_b0310","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","article-title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial","volume":"129","author":"Taub","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bcp.2022.115046_b0315","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2021012206","article-title":"High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial","volume":"138","author":"Hitzler","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bcp.2022.115046_b0320","first-page":"1677","article-title":"Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group","volume":"10","author":"Creutzig","year":"1996","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.bcp.2022.115046_b0325","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bcp.2022.115046_b0330","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2022.115046_b0335","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pbc.25789","article-title":"Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan","volume":"63","author":"Taga","year":"2016","journal-title":"Pediatric Blood Cancer"},{"issue":"34","key":"10.1016\/j.bcp.2022.115046_b0340","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1200\/JCO.2007.12.3687","article-title":"Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group","volume":"25","author":"Kudo","year":"2007","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115046_b0345","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41375-021-01157-w","article-title":"Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome","volume":"35","author":"Taga","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bcp.2022.115046_b0350","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1038\/s41375-021-01397-w","article-title":"Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome","volume":"35","author":"Taga","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bcp.2022.115046_b0355","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2012-03-414755","article-title":"Clinical characteristics and outcome of refractory\/relapsed myeloid leukemia in children with Down syndrome","volume":"120","author":"Taga","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bcp.2022.115046_b0360","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1200\/JCO.2003.11.066","article-title":"Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89\/91 protocol of the French Society of Pediatric Hematology and Immunology","volume":"21","author":"Aladjidi","year":"2003","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0365","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/cncr.22385","article-title":"Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia","volume":"109","author":"Rubnitz","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0370","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14737140.2021.1841640","article-title":"Pediatric relapsed acute myeloid leukemia: a systematic review","volume":"21","author":"Hoffman","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"10","key":"10.1016\/j.bcp.2022.115046_b0375","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bmt.1705844","article-title":"Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia","volume":"40","author":"Meissner","year":"2007","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0380","first-page":"533","article-title":"Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome","volume":"18","author":"Rubin","year":"1996","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.bcp.2022.115046_b0385","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2013.02.017","article-title":"Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome","volume":"19","author":"Hitzler","year":"2013","journal-title":"Biol. Blood Marrow Trans.: J. Am. Soc. Blood Marrow Trans."},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0390","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.leu.2401753","article-title":"Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?","volume":"14","author":"Frost","year":"2000","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bcp.2022.115046_b0395","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood.V87.8.3395.bloodjournal8783395","article-title":"Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia","volume":"87","author":"Taub","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2022.115046_b0400","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/0008-5472.CAN-03-2456","article-title":"The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines","volume":"64","author":"Ge","year":"2004","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.bcp.2022.115046_b0405","first-page":"6421","article-title":"Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome","volume":"60","author":"Taub","year":"2000","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0410","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jnci\/dji026","article-title":"GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia","volume":"97","author":"Ge","year":"2005","journal-title":"J. Natl Cancer Inst."},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0415","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/leu.2013.264","article-title":"Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy","volume":"28","author":"Stankov","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bcp.2022.115046_b0420","doi-asserted-by":"crossref","first-page":"e27414","DOI":"10.1002\/pbc.27414","article-title":"Effective response to azacitidine in a child with a second relapse of myeloid leukemia associated with Down syndrome after bone marrow transplantation","volume":"65","author":"Uemura","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0425","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1097\/MPH.0000000000001158","article-title":"Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia","volume":"41","author":"Becktell","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115046_b0430","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/leu.2016.164","article-title":"The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome","volume":"30","author":"Lee","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0435","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"9648","key":"10.1016\/j.bcp.2022.115046_b0440","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0445","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2022.115046_b0450","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/pbc.24918","article-title":"Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome","volume":"61","author":"Hitzler","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2022.115046_b0455","doi-asserted-by":"crossref","first-page":"e27700","DOI":"10.1002\/pbc.27700","article-title":"Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials","volume":"66","author":"Murphy","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2022.115046_b0460","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/01.mph.0000172223.04694.c4","article-title":"GATA1 mutation analysis demonstrates two distinct primary leukemias in a child with down syndrome; implications for leukemogenesis","volume":"27","author":"Hellebostad","year":"2005","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115046_b0465","doi-asserted-by":"crossref","first-page":"e26411","DOI":"10.1002\/pbc.26411","article-title":"Acute lymphoblastic leukemia in patients with Down syndrome with a previous history of acute myeloid leukemia","volume":"64","author":"Tomizawa","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2022.115046_b0470","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2016.23","article-title":"Low risk of solid tumors in persons with Down syndrome","volume":"18","author":"Hasle","year":"2016","journal-title":"Genet. Med.: Off. J. Am. College Med. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0475","first-page":"448","article-title":"A lack of neuroblastoma in Down syndrome: a study from 11 European countries","volume":"58","author":"Satg\u00e9","year":"1998","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2022.115046_b0480","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1203\/00006450-200006000-00002","article-title":"Susceptibility to leukemia and resistance to solid tumors in Down syndrome","volume":"47","author":"Zipursky","year":"2000","journal-title":"Pediatric Res."},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0485","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<929::AID-CNCR14>3.0.CO;2-Y","article-title":"An excess of testicular germ cell tumors in Down's syndrome: three case reports and a review of the literature","volume":"80","author":"Satg\u00e9","year":"1997","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2022.115046_b0490","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00043426-199903000-00012","article-title":"Intracranial germ cell tumors in children with and without Down syndrome","volume":"21","author":"Chik","year":"1999","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2022.115046_b0495","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.3389\/fimmu.2018.03058","article-title":"The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System","volume":"9","author":"Satg\u00e9","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2022.115046_b0500","doi-asserted-by":"crossref","first-page":"749480","DOI":"10.3389\/fgene.2021.749480","article-title":"Ten Reasons Why People With Down Syndrome are Protected From the Development of Most Solid Tumors \u2013 A Review","volume":"12","author":"Osuna-Marco","year":"2021","journal-title":"Front. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2022.115046_b0505","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0165-4608(03)00203-6","article-title":"Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature","volume":"147","author":"Satg\u00e9","year":"2003","journal-title":"Cancer Genet. Cytogenet."},{"issue":"5","key":"10.1016\/j.bcp.2022.115046_b0510","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.semcancer.2008.03.020","article-title":"Carcinogenesis in Down syndrome: what can be learned from trisomy 21?","volume":"18","author":"Satg\u00e9","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2022.115046_b0515","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pharmthera.2015.03.004","article-title":"DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications","volume":"151","author":"Abbassi","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2022.115046_b0520","doi-asserted-by":"crossref","first-page":"171639","DOI":"10.1155\/2012\/171639","article-title":"Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics","volume":"2012","author":"Cr\u00e9au","year":"2012","journal-title":"Neural Plasticity"},{"issue":"10","key":"10.1016\/j.bcp.2022.115046_b0525","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc3355","article-title":"Tumorigenesis in Down's syndrome: big lessons from a small chromosome","volume":"12","author":"Ni\u017eeti\u0107","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2022.115046_b0530","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/hmg\/ddg015","article-title":"ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway","volume":"12","author":"Wolvetang","year":"2003","journal-title":"Hum. Mol. Genet."},{"issue":"11","key":"10.1016\/j.bcp.2022.115046_b0535","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/sj.ejhg.5200721","article-title":"High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours","volume":"9","author":"Zorick","year":"2001","journal-title":"Europ. J. Human Genet.: EJHG"},{"issue":"7250","key":"10.1016\/j.bcp.2022.115046_b0540","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nature08062","article-title":"Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1","volume":"459","author":"Baek","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0545","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2013.08.047","article-title":"A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis","volume":"342","author":"Shin","year":"2014","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2022.115046_b0550","first-page":"11","article-title":"Down syndrome and microRNAs","volume":"8","author":"Br\u00e1s","year":"2018","journal-title":"Biomed. Reports"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522200140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522200140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:13:17Z","timestamp":1762096397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522200140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":110,"alternative-id":["S000629522200140X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115046","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The paradox of Myeloid Leukemia associated with Down syndrome","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115046"}}